BRAF and colorectal carcinoma: In advanced CRC, the evaluation of RAS genes’ (NRAS, KRAS) mutational status is recommended for predicting therapeutic response, while the assessment of the BRAF gene’s mutational status is conducted for prognostic purposes [3,10,15].